A randomized study comparing the efficacy of mometasone furoate and fluticasone furoate on the ocular and nasal symptoms of allergic rhinitis

Background: Ocular symptoms like itching, redness and congestion are common in patients with allergic rhinitis. These symptoms affect the quality of life and increase the burden on the healthcare cost. Intranasal steroids are effective in reducing the nasal and ocular symptoms of allergic rhinitis. We aim to compare the efficacy of mometasone furoate nasal spray and fluticasone furoate nasal spray in reducing the nasal and ocular symptoms of allergic rhinitis.Methods: 90 patients with perennial allergic rhinitis and ocular symptoms were randomly divided into 2 groups. Group A (n=46) received 200 µg of mometasone furoate nasal spray once daily and Group B (n=44) received 110 µg of fluticasone furoate nasal spray daily. The patients were assessed by total ocular symptom score [TOSS] and total nasal symptom score [TNSS] at 2, 6 and 12 weeks interval. Results: There was a statistically significant reduction in both the groups in respect to the TOSS and TNSS scores. However the improvement in the TOSS score in the fluticasone furoate group was more than the mometasone furoate group by 6 weeks (p=0.0009), which continued till the 12 weeks (p=0.045).Conclusions: Fluticasone furoate is more effective than mometasone furoate in managing the ocular and nasal symptoms of allergic rhinitis.

Download Full-text

Efficacy of Mometasone Furoate and Fluticasone Furoate on Persistent Allergic Rhinoconjunctivitis

Allergy & Rhinology ◽

10.2500/ar.2013.4.0065 ◽

2013 ◽

Vol 4 (3) ◽

pp. ar.2013.4.0065 ◽

Cited By ~ 6

Author(s):

W. Hamizan Aneeza ◽

Salina Husain ◽

Roslenda Abdul Rahman ◽

Dexter Van Dort ◽

Asma Abdullah ◽

...

Keyword(s):

Symptom Score ◽

Nasal Symptom ◽

Allergic Rhinoconjunctivitis ◽

Mometasone Furoate ◽

Fluticasone Furoate ◽

Ocular Symptoms ◽

Nasal Symptoms ◽

Total Nasal Symptom Score ◽

Significant Difference ◽

Symptom Scores

Allergic rhinoconjunctivitis denotes both nasal and ocular manifestation of allergy, which may be solely treated with intranasal steroid. This study compares the efficacy of mometasone furoate nasal spray (NS) and fluticasone furoate NS in treatment of allergic rhinoconjunctivitis. The secondary objective is to study the severity of baseline ocular symptoms in allergic rhinoconjunctivitis. Seventy-eight patients with allergic rhinoconjunctivitis were assessed subjectively and objectively using twice-daily symptom scores for nasal (reflective total nasal symptom score [rTNSS] and instantaneous TNSS [iTNSS]) and ocular (reflective total ocular symptom score [rTOSS] and instantaneous TOSS [iTOSS]) symptoms, rhinoconjunctivitis quality-of-life questionnaires (RQOLQs), and acoustic rhinometry. All measurements were taken at baseline and at 4 and 8 weeks of treatment. Sixty-three patients who were randomized into the mometasone furoate group (n = 36) and the fluticasone furoate group (n = 27) completed the study. Seventy-six percent of patients had mild ocular symptoms, 20.5% had moderate symptoms, and only 2.6% had severe symptoms at baseline based on the iTOSS; 65.1% had mild nasal symptoms and 3% had severe nasal symptoms. There was significant reduction in the symptom scores after 1 week (p < 0.05). Both groups had significant improvement in RQOLQ scores after 1 month, which further improved at 2 months (p < 0.05). The nasal dimensions also improved in both groups (p < 0.05) but there was no statistically significant difference between groups. Both mometasone furoate and fluticasone furoate are effective as single-modality treatment of allergic rhinoconjunctivitis. The majority of patients manifest mild ocular symptoms that may be solely treated with intranasal steroids.

Download Full-text

The role of budesonide and mometasone furoate on the nasal and sinus symptoms in allergic rhinosinuitis: a randomized study

International Journal of Otorhinolaryngology and Head and Neck Surgery ◽

10.18203/issn.2454-5929.ijohns20195193 ◽

2019 ◽

Vol 6 (1) ◽

pp. 15

Author(s):

Sriram Govindaraj ◽

Ganeshbala Arivazhagan ◽

Jayendiran Subramani ◽

Jinu Vadakkanethu Iype ◽

Ilango Chakkravarthy

Keyword(s):

Allergic Rhinitis ◽

Nasal Spray ◽

Work Performance ◽

Randomized Study ◽

Nasal Symptom ◽

Mometasone Furoate ◽

Budesonide Group ◽

Group B ◽

The Individual

Background: Allergic rhinosinuitis is one of the common clinical problems that otorhinolaryngologist faces daily. Sinusitis symptoms like headache, facial pain and eyelid oedema are frequent in patients with allergic rhinitis, which in turn will affect the cognitive function, productivity and quality of life which impair the efficiency of the individual work performance. It may result in a prescription for antibiotics but the role of antibiotics is debated. Anti-inflammatory drugs such as intranasal steroids play a major role in reducing the symptoms of allergic rhinitis. We plan to compare the efficacy of budesonide nasal spray with mometasone furoate nasal spray in reducing the nasal and sinus symptoms of allergic rhinosinusitis.Methods: 146 patients of allergic rhinitis with sinusitis symptoms were randomly divided into 2 groups as Group A (n=70) received 256 μg budesonide nasal spray of once daily and Group B (n=76) received 200 μg of mometasone furoate nasal spray daily. The patients were assessed by sino-nasal outcome test (SNOT) score and total nasal symptom score (TNSS) at 2, 6 and 12 weeks interval. Results: There is significant reduction in both the groups, in respect to the SNOT and TNSS scores. We also observed significant improvement in the SNOT score in the budesonide group when compared with the mometasone furoate group by 6weeks which continued till the 12 weeks (p=0.001).Conclusions: Budesonide nasal spray is more effective than mometasone furoate spray in managing both sinus and nasal symptoms in allergic rhinitis.

Download Full-text

Therapeutic comparability of Dezrinit and Nazonex® in control of symptoms of allergic rhinitis. The results of a multicenter, open, randomized, comparative study in parallel groups

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja392 ◽

2016 ◽

Vol 13 (3) ◽

pp. 65-74

Author(s):

N I Ilina ◽

T G Fedoskova ◽

N G Astafieva ◽

L A Gorychkina ◽

A S Edin ◽

...

Keyword(s):

Allergic Rhinitis ◽

Symptom Score ◽

Nasal Spray ◽

Nasal Symptom ◽

Ocular Symptom ◽

Mometasone Furoate ◽

Total Nasal Symptom Score ◽

Metered Dose ◽

Comparison Groups ◽

Receive Treatment

Background. To study efficacy and safety of Dezrinit (mometasone furoate, metered dose nasal spray, 200 pg/day) in comparison with Nasonex® (mometasone furoate, metered dose nasal spray, 200 pg/day) upon administration for 14 days in adult patients with seasonal allergic rhinitis. Materials and methods. A total of 141 patients were enrolled into the study at 8 study centers in the RF, of which 134 patients were randomized: 67 patients into the experimental group (Dezrinit) and 67 patients into the comparison group (Nasonex®). patients were randomized to receive treatment either with Dezrinit or Nasonex®. Efficacy was assessed based on reflective Total Nasal Symptom Score (rTNSS) and instantaneous Total Nasal Symptom Score (iTNSS); reflective Total Ocular Symptom Score (rTOSS) and instantaneous Total Ocular Symptom Score (iTOSS). Overall proportion of patients who responded to treatment was evaluated according to overall assessment of treatment efficacy both by a patient and by an investigator. AEs were reported for safety assessment. Results. After 14 days of treatment a marked improvement of symptoms was observed in both groups based on all assessed scores. Mean change (SD) in rTNSS from baseline was -11,91 (4,625) scores and -11,64 (4,58) scores in the experimental and comparison groups, respectively (within group differences, p

Download Full-text

Effectiveness of Oral Antihistamines and Intranasal Steroid Spray in relieving Ocular Symptoms in Allergic Rhinitis using Total Ocular Symptom Score

Otorhinolaryngology Clinics - An International Journal ◽

10.5005/jp-journals-10003-1226 ◽

2016 ◽

Vol 8 (2) ◽

pp. 45-50

Author(s):

Namit K Singh ◽

Prakash S Nagpure ◽

Manish K Yadav ◽

Shushil Chavan ◽

Shraddha Manpe ◽

...

Keyword(s):

Allergic Rhinitis ◽

Symptom Score ◽

Controlled Trial ◽

Statistical Significance ◽

Ocular Symptom ◽

Mometasone Furoate ◽

Chi Square ◽

Ocular Symptoms ◽

Intranasal Corticosteroid Spray ◽

Group B

ABSTRACT Ocular symptoms in allergic rhinitis are often overlooked, but they have a significant impact on the quality of life of an individual. Materials and methods A randomized controlled trial was conducted from August 2012 to July 2013; a total of 153 cases were considered and divided into two groups. Group A received levocetirizine, and group B received mometasone furoate nasal spray. Aims and objectives The aims and objectives of this study were to determine the total ocular symptom score (TOSS) according to the severity of allergic rhinitis, determine the TOSS before medication, and determine the effectiveness of antihistamines (levocetirizine) and intranasal corticosteroid spray (mometasone furoate). Results The results indicate average TOSS to be in intermittent mild (51.32), intermittent moderate to severe (55.86), persistent mild (44.50), and persistent moderate to severe (52.02). Chi-square test to compare the relief between groups A and B did not show any statistical significance after 1st (p = 0.8951) and 4th weeks (p = 0.9758) of follow-up. How to cite this article Singh NK, Nagpure PS, Yadav MK, Chavan S, Manpe S, Ganeshkar R. Effectiveness of Oral Antihistamines and Intranasal Steroid Spray in relieving Ocular Symptoms in Allergic Rhinitis using Total Ocular Symptom Score. Int J Otorhinolaryngol Clin 2016;8(2):45-50.

Download Full-text

A Patient Preference Study that Evaluated Fluticasone Furoate and Mometasone Furoate Nasal Sprays for Allergic Rhinitis

Allergy & Rhinology ◽

10.2500/ar.2016.7.0185 ◽

2016 ◽

Vol 7 (4) ◽

pp. ar.2016.7.0185 ◽

Cited By ~ 4

Author(s):

Anahi Yanez ◽

Alex Dimitroff ◽

Peter Bremner ◽

Chae-Seo Rhee ◽

Graham Luscombe ◽

...

Keyword(s):

Allergic Rhinitis ◽

Nasal Spray ◽

Patient Preference ◽

Patient Adherence ◽

Sensory Attributes ◽

Mometasone Furoate ◽

Study Patient ◽

Fluticasone Furoate ◽

Nasal Sprays ◽

Nasal Irritation

Background Corticosteroid nasal sprays are the mainstay of treatment for allergic rhinitis. These sprays have sensory attributes such as scent and/or odor, taste and aftertaste, and run down the throat and/or the nose, which, when unpleasant, can affect patient preference for, and compliance with, treatment. Objective This study examined patient preference for fluticasone furoate nasal spray (FFNS) or mometasone furoate nasal spray (MFNS) based on their sensory attributes after administration in patients with allergic rhinitis. Methods This was a multicenter, randomized, double-blind, cross-over study. Patient preferences were determined by using three questionnaires (Overall Preference, Immediate Attributes, and Delayed Attributes). Results Overall, 56% of patients stated a preference for FFNS versus 32% for MFNS (p < 0.001); the remaining 12% stated no preference. More patients stated a preference for FFNS versus MFNS for the attributes of “less drip down the throat” (p < 0.001), “less run out of the nose” (p < 0.05), “more soothing” (p < 0.05), and “less irritating” (p < 0.001). More patients responded in favor of FFNS versus MFNS for the immediate attributes, “run down the throat” (p < 0.001), and “run out of the nose” (p < 0.001), and, in the delayed attributes, “run down the throat” (p < 0.001), “run out of the nose” (p < 0.01), “presence of aftertaste” (p < 0.01), and “no nasal irritation” (p < 0.001). Conclusion Patients with allergic rhinitis preferred FFNS versus MFNS overall and based on a number of individual attributes, including “less drip down the throat,” “less run out of the nose,” and “less irritating.” Greater preference may improve patient adherence and thereby improve symptom management of the patient's allergic rhinitis.

Download Full-text